Over the course of the summer, RKEO has been running a number of training sessions with Vertigo Ventures aimed at supporting academics to develop the impact of their research.
The next two sessions are booked for Monday 3 July (one between 9am – 12:15pm and one between 1:15pm – 4:30pm) and will take place at an off campus location. Lunch and refreshments will be provided.
The aims of the training as follows:
- Attendees will have identified what their intended impact could be by 2020 and what knowledge exchange/impact acceleration activities they should be looking to do over the next year
- Attendees will have developed a workable plan for their potential (REF2021) impact case studies between now and 2020
- Attendees will have identified what kind of evidence will be gathered and how this will be obtained.
The session is being run by Laura Fedorciow and Shireen Ali-Khan of Vertigo Ventures, one of the few established specialist firms operating in this arena.
Places are being offered on a first come, first serve basis. Please email Rachel Bowen rbowen@bournemouth.ac.uk to book your place.
What makes good evidence of research impact?










Reminder: Recharge Your Research Routine Next Week for World Wellbeing Week
Boost Your Research Toolkit: Digital Confidence & AI Literacy Workshop – Friday 26 June 10am-12pm
BU students’ publishing success
BU presentation at the University of Bristol
Art and Design: History, Practice and Theory academics – would you like to get more involved in preparing our next REF submission?
Horizon Europe Cluster 3 (Civil Security for Society) 2026 Calls Now Open
MSCA Doctoral Networks 2026 Call Information Webinar
ESRC Festival of Social Science 2026: Application Deadline Extended to Thursday 25 June 2026
Reminder: Register for the ESRC Festival of Social Science 2026 Information Session
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease